The 3,750 Shares of Acorda Therapeutics Inc. (ACOR) Stock are sold by Jane Wasman

The 3,750 Shares of Acorda Therapeutics Inc. (ACOR) Stock are sold by Jane Wasman

Acorda Therapeutics Inc. (NASDAQ:ACOR) insider Jane Wasman sold 3,750 shares of the business’s stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $20.78, for a total value of $77,925.00. Following the sale, the insider now directly owns 105,021 shares in the company, valued at $2,182,336.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Jane Wasman also recently made the following trade(s): On Friday, September 23rd, Jane Wasman sold 500 shares of Acorda Therapeutics stock. The stock was sold at an average price of $27.32, for a total value of $13,660.00.

Acorda Therapeutics Inc. (NASDAQ:ACOR) opened at 19.82 on Monday. The company’s market cap is $913.50 million. Acorda Therapeutics Inc. has a 52 week low of $19.72 and a 52 week high of $43.63. The company has a 50-day moving average price of $24.04 and a 200 day moving average price of $25.80.

Acorda Therapeutics (NASDAQ:ACOR) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.18 by $0.11. The company earned $127.45 million during the quarter, compared to analysts’ expectations of $128.33 million. Acorda Therapeutics had a negative net margin of 1.08% and a positive return on equity of 1.00%. The company’s quarterly revenue was up 12.1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.31 earnings per share. On average, equities research analysts forecast that Acorda Therapeutics Inc. will post $0.47 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of ACOR. FMR LLC raised its position in shares of Acorda Therapeutics by 14.4% in the second quarter. FMR LLC now owns 6,898,009 shares of the biopharmaceutical company’s stock worth $175,934,000 after buying an additional 865,845 shares in the last quarter. Vanguard Group Inc. raised its position in Acorda Therapeutics by 21.6% in the second quarter. Vanguard Group Inc. now owns 4,268,679 shares of the biopharmaceutical company’s stock worth $108,872,000 after buying an additional 759,257 shares during the period. Scopia Capital Management LP raised its position in Acorda Therapeutics by 35.9% in the first quarter. Scopia Capital Management LP now owns 2,655,533 shares of the biopharmaceutical company’s stock worth $70,239,000 after buying an additional 702,110 shares during the period. State Street Corp raised its position in Acorda Therapeutics by 1.6% in the second quarter. State Street Corp now owns 1,478,289 shares of the biopharmaceutical company’s stock worth $37,707,000 after buying an additional 22,818 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in Acorda Therapeutics by 14.8% in the second quarter. Dimensional Fund Advisors LP now owns 1,346,545 shares of the biopharmaceutical company’s stock worth $34,344,000 after buying an additional 173,635 shares during the period.

ACOR has been the topic of several analyst reports. TheStreet cut Acorda Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, July 28th. Leerink Swann initiated coverage on Acorda Therapeutics in a research note on Tuesday, October 4th. They set a “market perform” rating and a $25.00 price objective on the stock. Stifel Nicolaus reissued a “buy” rating on shares of Acorda Therapeutics in a research note on Thursday, August 25th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Acorda Therapeutics in a research note on Thursday, August 25th. Finally, Cowen and Company reissued an “outperform” rating and set a $65.00 price objective on shares of Acorda Therapeutics in a research note on Thursday, August 25th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $39.63.

Acorda Therapeutics Company Profile

Related posts

Leave a Comment